Reversibility of Central Nervous System Adverse Events in Course of Art
Authors:
- Lucia TaramassoLTLucia Taramasso
- Giancarlo OrofinoGOGiancarlo Orofino
- Elena RicciERElena Ricci
- Barbara MenzaghiBMBarbara Menzaghi
- Giuseppe Vittorio De SocioGiuseppe Vittorio De Socio
- Nicola SquillaceNSNicola Squillace
- Giordano MadedduGiordano Madeddu
- Francesca VichiFVFrancesca Vichi
- Benedetto Maurizio CelesiaBCBenedetto Maurizio Celesia
- Chiara MolteniCMChiara Molteni
- Federico ContiFCFederico Conti
- Filippo Del PuenteFPFilippo Del Puente
Open Access
Abstract
The purpose of this study is to evaluate the frequency of central nervous system adverse events (CNS-AE) on dolutegravir (DTG) and non-DTG containing ART, and their reversibility, in the observational prospective SCOLTA cohort. Factors associated with CNS-AE were estimated using a Cox proportional-hazards model. 4939 people living with HIV (PLWH) were enrolled in DTG (n = 1179) and non-DTG (n = 3760) cohorts. Sixty-six SNC-AE leading to ART discontinuation were reported, 39/1179 (3.3%) in DTG and 27/3760 (0.7%) in non-DTG cohort. PLWH naïve to ART, with higher CD4 + T count and with psychiatric disorders were more likely to develop a CNS-AE. The risk was lower in non-DTG than DTG-cohort (aHR 0.33, 95% CI 0.19–0.55, p < 0.0001). One-year follow-up was available for 63/66 PLWH with CNS-AE. AE resolution was reported in 35/39 and 23/24 cases in DTG and non-DTG cohorts, respectively. The probability of AE reversibility was not different based on ART class, sex, ethnicity, CDC stage, or baseline psychiatric disorder. At the same time, a lower rate of event resolution was found in PLWH older than 50 years (p = 0.017). In conclusion, CNS-AE leading to ART discontinuation was more frequent in DTG than non-DTG treated PLWH. Most CNS-AE resolved after ART switch, similarly in both DTG and non-DTG cohorts.Keywords
This publication has 56 references indexed in Scilit:
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionNew England Journal of Medicine, 2013
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trialThe Lancet Infectious Diseases, 2013
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyThe Lancet, 2013
- Dolutegravir in antiretroviral-naive adults with HIV-1AIDS, 2013
- Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)Biomedicine & Pharmacotherapy, 2013
- Raltegravir central nervous system tolerability in clinical practiceAIDS, 2012
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialThe Lancet, 2011
- Efficacy and safety of boosted and unboosted atazanavir‐containing antiretroviral regimens in real life: results from a multicentre cohort studyHIV Medicine, 2009
- Updated research nosology for HIV-associated neurocognitive disordersNeurology, 2007
- Underdiagnosis of depression in HIVJournal of General Internal Medicine, 2003